the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
Published 7 months ago • 89 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
1:44
the genomics of rt and prognostic implications of rt characterization
-
2:09
ctcs as a prognostic indicator in patients with newly diagnosed multiple myeloma
-
4:48
an insight into the management of cytopenias in mf
-
1:14
modern prognostication in mpns: improving risk stratification & treatment approaches
-
1:47
shared treatment decision-making
-
3:03
the evolution of treatment patterns and prognostic biomarkers in latin american cll patients
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
1:11
personalized risk assessment for transplantation in primary immunodeficiency disorders
-
1:21
the prognostic impact of secondary-type mutations in patients with favorable risk aml
-
3:59
pv: outcomes, unmet needs, and therapeutic strategies
-
2:12
barriers to the implementation and standardization of ai in the clinic
-
1:05
the future of managing precursor conditions
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:23
developing a pro collection tool for patients with scd: key themes which are important to patients
-
3:31
relevance of the ipss-r during sct in patients with mds in the molecular classification era
-
1:51
targeting complement to treat pnh and other hematologic diseases
-
14:38
hematology in 10 min hemostasis and coagulation mp4 final
-
3:40
master class in transplantation and hematology: highlights
-
2:13
splicing mutations in post-et/post-pv myelofibrosis